Navigation Links
World's largest DNA scan for autism uncovers new gene variant for disorder
Date:4/28/2009

UCLA scientists, in partnership with 30 research institutions across the country, have identified a new gene variant that is highly common in autistic children. And when researchers scrutinized the activity of the gene, known as CDH10, in the fetal brain, they discovered that it is most active in key regions that support language, speech and interpreting social behavior.

Published April 28 in the advance online edition of the journal Nature, the two findings suggest that CDH10 plays a critical role in shaping the developing brain and may contribute to a prenatal risk of autism.

A variant is a gene that has undergone subtle changes from the normal DNA yet is shared by a significant portion of the population.

"While this gene variant is common in the general population, we discovered that it occurs about 20 percent more often in children with autism," said study author Dr. Daniel Geschwind, director of the UCLA Center for Autism Treatment and Research. "A major change like this in the genetic code is too common to be a simple mutation it is a risk factor in the origin of the disease."

Using the largest population sample to date, the scientists systematically scanned the DNA of 3,100 individuals from 780 families nationwide. Each family had at least two autistic children.

The scan connected autism to a specific region of chromosome 5, which previous studies at UCLA and collaborating institutions had pinpointed as a hub for genetic variations linked to higher autism risk.

To verify the findings, Dr. Hakon Hakonarson at the Children's Hospital of Pennsylvania led the team in conducting a second scan on the DNA of 1,200 individuals from families affected by autism, as well as nearly 6,500 healthy controls. All participants shared European ancestry.

The scientists evaluated the relationship of more than half a million gene variants to autism and consistently discovered six changes that o
'/>"/>

Contact: Roxanne Moster
rmoster@mednet.ucla.edu
310-794-2264
University of California - Los Angeles
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Gunther Von Hagens BODY WORLDS and KORPERWELTEN - Not Affiliated With Paris Copycat Display
2. BODY WORLDS Exhibition Uses Lung Specimens to Launch Anti-Smoking Campaign at the San Diego Natural History Museum
3. HHS AIDS.gov to Use Blogs, Virtual Worlds, and Social Networks to Deliver HIV Information for World AIDS Day 2008
4. Gunther von Hagens BODY WORLDS Exhibitions Welcome Specimens From Worlds First Living Body Donor for Plastination
5. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
6. California Science Center Welcomes 1-Millionth BODY WORLDS Visitor
7. Specimens in BODY WORLDS Exhibitions Stem Primarily from German Body Donation Program
8. The Institute for Plastination Responds to the Bishop of Manchesters Media Blitz, Assertions, and Allegations About BODY WORLDS Anatomical Exhibition Coming to Manchester
9. Museum Open Around the Clock - BODY WORLDS 2 and The Tech Host 40 Hour Marathon!
10. BODY WORLDS 3 & The Story of the Heart Opens at the California Science Center, March 14, 2008
11. BODY WORLDS 2 & Breathe California Pair Up for Some Ash Kicking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... offer a new way to detect and treat autism during ... months of life, when the brain is ... agree that,the earlier autism is diagnosed and therapy begun, the ... even when parents have an intuition,that "something is amiss" with ...
... Low Fat, Rich and Creamy Beverage ... FULLERTON, Calif., March 11 Wildwood Organics, a,division of ... today launched Probiotic Soymilk(TM). This delicious beverage is,certified organic, ... of soy protein per serving. Probiotic Soymilk(TM) is also ...
... a global,leader in dental and aesthetic lasers, today ... tissue lasers will receive a,tuition-free introductory laser certification ... dental laser education. The partnership is,the latest milestone ... education., "We fully recognize that training is ...
... and Phase II Trials, with Some Patients Already Past the Expected Median Average ... Survival Time for This Population -, - Data From Dosimetry Trial ... ... March 11 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ...
... March 10 As a longtime resident of Southern,Nevada, ... who have been,affected by this situation. I understand that ... against me and the Endoscopy Center of,Southern Nevada. While ... I,am unfortunately unable to do so at this time ...
... N.C., March 10 Cogdell Spencer,Inc. (NYSE: CSA ... 100,percent of the stock of Marshall Erdman and Associates. ... integrated healthcare real estate,company in the country, with over ... on January 23, 2008, was financed,through a $100 million ...
Cached Medicine News:Health News:Autism Awareness Month - New Hope for Detecting/Reversing Autism in Infants 2Health News:Wildwood Organics Introduces Probiotic Soymilk(TM) 2Health News:HOYA ConBio Partners With Advanced Laser Training to Offer Complementary Laser Certification Course in Dentistry 2Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 2Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 3Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 4Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 5Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 6Health News:Cogdell Spencer Inc. Announces the Closing of the Marshall Erdman and Associates Merger 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... January 11, 2012 Simbionix USA Corporation, ... training, is pleased to announce that advanced virtual reality ... in addition to English. The new languages ... system, MentorLearn™. MentorLearn is available either as the new ...
... 11, 2012  Suneva Medical, a privately-held aesthetic medical device ... study to investigate the efficacy of Artefill for the ... being conducted at 10 centers throughout the U.S. and ... "Acne can have lasting effects on a patient,s ...
Cached Medicine Technology:Simbionix Comprehensive Medical Simulators now Available in Additional Languages 2Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study 2
Standard knife with box, C profile...
... The Cryostage freezing stage is a refrigerated ... object holder, primarily for use with the 8000 ... other sledge microtomes. ,The refrigerated stage gives a ... the surface is ridged to provide good adhesion ...
... necessary to cool a specimen below room temperature. ... most microtomes and will permit specimen cooling from ... The equipment consists of a cooling stage and ... suited for operation with a base sledge microtome, ...
... MNL 4404 & 4405 series Freezing Stages fit ... have no moving parts and need only the ... for operation. Freezing starts immediately and ... adjustable so that optimum cutting temperatures can be ...
Medicine Products: